September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE Trial presented in a Hot Line LBCT Session at ESC Congress. Rates of bleeding were similar between the two groups.

September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause mortality and hospitalization for worsening heart failure, when heart failure patients with atrial fibrillation (AF) are treated with catheter ablation, compared to pharmacological therapy recommended by current guidelines. The outcomes were presented at a Late-Breaking Clinical Trials Hot Line session during the European Society of Cardiology’s ESC Congress 2017 in Barcelona.

September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority.

Advances in FFR, FFR-CT, was the most popular cardiology story in August 2017.

September 1, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of August, based on website analytics of the month’s 113,188 pageviews:  

 

Top Articles

1. What is New in FFR Technology

2. Radiation Exposure Related to Transradial Access

Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advances. Many of the limitations in echocardiography has been due to the limits of image processing speeds. This has limited the image quality based on how much data can be processed and rendered on the ultrasound system screen in real time. 

Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study found statistically significant and clinically important blood pressure reductions in the patients treated with renal denervation (RDN) across both office and ambulatory systolic and diastolic measurements. The data in the first 80 patients enrolled in the study at three months were presented in a late-breaking clinical trial session at the European Society of Cardiology (ESC) meeting, Aug. 26-30 in Barcelona, Spain and published simultaneously in The Lancet.

Society of Cardiovascular Computed Tomography (SCCT) London

GE Healthcxare Signa Pioneer MAGIC six contrasts in one scan software by SyntheticMR.

August 31, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for SyntheticMR’s SyMRI. The magnetic resonance imaging (MRI) software delivers multiple, adjustable contrast images and quantitative data from a single five to six minute scan. The software reduces the need for several scans using different protocols, helping to reduce scan times and increases patient throughput. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now